Pfizer Cuts Last AAV Gene Therapy Program By Taking Beqvez Off The Market
Product Saw Zero Sales Since April Approval
Pfizer cited many reasons for ending sales of hemophilia B gene therapy Beqvez, including a lack of patient and doctor interest. The company no longer plans to develop AAV gene therapies.
